IOL Chemicals & Pharmaceuticals reported a strong performance for Q2 FY27, with net profit surging to Rs 65.07 crore from Rs 29.97 crore a year ago. Revenue rose significantly to Rs 795.03 crore, driven by growth across its pharmaceutical and chemical segments. The company also marked the first-time consolidation of its new UK subsidiary, IOL Pharmaxis.
IOL Chemicals & Pharmaceuticals Q2 Net Profit Soars
Revenue: Rs 795.03 crore | Net Profit: Rs 65.07 crore
Reader Takeaway: Strong operational momentum across segments and the addition of a UK subsidiary drive significant earnings growth.
What just happened
IOL Chemicals & Pharmaceuticals Limited announced its unaudited financial results for the quarter and half-year ended September 30, 2026. The board approved the financials on October 30, 2026, reporting a substantial year-on-year increase in profitability. Consolidated revenue reached Rs 795.03 crore for the quarter, up from Rs 567.53 crore in the same period last year. Net profit more than doubled to Rs 65.07 crore, compared to Rs 29.97 crore previously.
Why this matters
The results highlight effective operational scaling. The Pharmaceutical segment remains a major contributor, delivering Rs 68.05 crore in profit on revenues of Rs 472.75 crore. Meanwhile, the Chemical segment added Rs 23.18 crore in profit from Rs 394.49 crore in revenue. These figures demonstrate the company's ability to maintain margins while expanding its top line.
The backstory
The half-year performance reflects a broader upward trajectory, with total revenue for the six-month period climbing to Rs 1,551.29 crore, compared to Rs 1,119.22 crore in the corresponding half-year of 2025. Net profit for the half-year stands at Rs 129.47 crore, a sharp improvement over the Rs 63.90 crore recorded in the prior year.
What changes now
This quarter marked the first-time consolidation of IOL Pharmaxis UK Limited, which commenced operations on April 2, 2026. This integration marks a strategic step in the company's international expansion efforts. The statutory auditors have issued an unmodified limited review report, confirming the integrity of the financial statements.
What to track next
Investors should focus on the contribution of the UK subsidiary to the group’s bottom line in future quarters. Ongoing monitoring of input costs and segment-specific demand will be crucial to assessing whether this growth pace is sustainable.